CIK 0000818033 · Accelerated filer
HERON THERAPEUTICS, INC. /DE/
Sign in to watch- Ticker
- HRTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 942875566
- Phone
- 8582514400
- Business address
- 4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA, 92121
- Former names
- AP PHARMA INC /DE/, ADVANCED POLYMER SYSTEMS INC /DE/
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-04-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise · Restricted Stock Units | −1,250 | 7,500 | ||
| 2023-04-13 | MANHARD KIMBERLY EVP, Drug Development | Option exercise · Restricted Stock Units | −4,564 | 27,936 | ||
| 2023-04-03 | Collard Craig A Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +3,000,000 | 3,000,000 | ||
| 2023-04-03 | Collard Craig A Chief Executive Officer | Grant or award · Restricted Stock Units | +250,000 | 250,000 | ||
| 2023-04-03 | Collard Craig A Chief Executive Officer | Grant or award · Employee Performance Stock Option (Right to Buy) | +4,250,000 | 4,250,000 | ||
| 2023-02-22 | Morgan Adam Director | Grant or award | +37,879 | 37,879 | ||
| 2023-02-22 | Morgan Adam Director | Grant or award · Stock Option (Right to Buy) | +227,272 | 227,272 | ||
| 2023-01-18 | Szekeres David Leslie EVP, Chief Operating Officer | Grant or award · Performance Stock Units | +49,788 | 49,788 | ||
| 2023-01-18 | Quart Barry D Chief Executive Officer | Grant or award · Employee Stock Option (Right to Buy) | +850,000 | 850,000 | ||
| 2023-01-18 | POYHONEN JOHN President & CCO | Grant or award · Performance Stock Units | +66,385 | 66,385 | ||
| 2023-01-18 | Peraza Lisa VP, Chief Accounting Officer | Grant or award · Performance Stock Units | +42,631 | 42,631 | ||
| 2023-01-18 | MANHARD KIMBERLY EVP, Drug Development | Grant or award · Performance Stock Units | +149,365 | 149,365 | ||
| 2023-01-13 | Szekeres David Leslie EVP, Chief Operating Officer | Option exercise | +1,250 | 23,598 | ||
| 2023-01-13 | Szekeres David Leslie EVP, Chief Operating Officer | Option exercise | +4,564 | 28,162 | ||
| 2023-01-13 | Szekeres David Leslie EVP, Chief Operating Officer | Shares withheld for taxes | −2,012 | $3.17 | $6K | 26,150 |
| 2023-01-13 | Szekeres David Leslie EVP, Chief Operating Officer | Option exercise · Restricted Stock Units | −1,250 | 8,750 | ||
| 2023-01-13 | Szekeres David Leslie EVP, Chief Operating Officer | Option exercise · Restricted Stock Units | −4,564 | 32,500 | ||
| 2023-01-13 | Quart Barry D Chief Executive Officer | Option exercise | +3,645 | 167,086 | ||
| 2023-01-13 | Quart Barry D Chief Executive Officer | Option exercise | +16,122 | 183,208 | ||
| 2023-01-13 | Quart Barry D Chief Executive Officer | Shares withheld for taxes | −5,219 | $3.17 | $17K | 177,989 |
Page 16 of 28 · 557 trades